ArticlePharmacoEconomics2018

Optimality, Future and Terminal Costs: Comment on "Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran".

Noga Gershon et al.PubMed ↗Publisher ↗

No numbers read from the abstract.